HI
BLCM

HBK Investments’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

HBK Investments’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,000
Closed -$370K – 1049
2017
Q1 		$370K Buy
+3,000
New +$393K ﹤0.01% 565

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

HBK Investments's BLCM Position: Q2 2017 in Review

HBK Investments sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2017, closing a stake of 3,000 shares — an estimated $370K sold.

HBK Investments first reported a position in BLCM in Q1 2017 and held it in 1 quarter. The position peaked at $370K in Q1 2017. 84 funds tracked by Wall St. Rank hold BLCM as of Q2 2017.

  • HBK Investments reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • HBK Investments sold 3,000 Bellicum Pharmaceuticals, Inc. shares in Q2 2017, an estimated $370K.
  • HBK Investments first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2017 and held it in 1 quarter.
  • HBK Investments's Bellicum Pharmaceuticals, Inc. position peaked at $370K in Q1 2017.
  • 84 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2017.

Based on HBK Investments's 13F filing for Q2 2017, filed 14 Aug 2017.